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Abstract
Background: Biomarkers of exposures such as infection or environmental chemicals can be measured in small
volumes of blood extracted from newborn dried blood spots (DBS) underscoring their potential utility for
population-based research. However, few studies have evaluated the feasibility and utility of this resource;
particularly the factors associated with parental consent, and the ability to retrieve banked samples with sufficient
remaining volume for epidemiologic research.
Methods: At 8 months postpartum, 5,034 mothers of infants born (2008–2010) in New York (57 counties excluding
New York City) were asked to consent for the use of residual DBS for the quantification of cytokines and
environmental chemicals. Mothers were part of the Upstate KIDS study, a longitudinal birth cohort designed to
evaluate child development through 3 years of age. Information on parental and infant characteristics was obtained
from birth certificates and maternal report at 4 months postpartum. Multivariate logistic regression was used to
identify factors associated with parental consent and with successful retrieval of DBS.
Results: Sixty-two percent (n = 3125) of parents consented. Factors significantly associated with consent included
non-Hispanic ethnicity (odds ratio 2.04; 95 % CI: 1.43–2.94), parity (1.29; 1.05–1.57), maternal obesity (1.42; 1.11–1.80)
and reported alcohol use during pregnancy (1.51; 1.12–2.06). However, these associations corresponded to small
absolute differences in proportions (4 to 8 %), suggesting that the two groups remained comparable. Infant
characteristics such as preterm delivery did not significantly differ by consent status among singletons and only
ventilator use (OR 2.39; 95 % CI: 1.06–5.41) remained borderline significant among twins in adjusted analyses.
Among consented infants, 99 % had at least one 3.2 mm punch successfully retrieved for biomarker analyses and
84 % had a full DBS circle available.
Conclusion: Parental characteristics varied slightly by consent, and the availability of samples for research purposes
was high, demonstrating the feasibility of this resource for population based research.
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Background
Newborn dried blood spots (DBS) can be an invaluable
source of biological specimens for population based re-
search studies requiring large sample sizes to capture
rare outcomes or for establishing a baseline measure in
birth cohorts for longitudinal comparisons. Techno-
logical advances have allowed for quantification of many
environmental and biological markers even when sample
volume is small [1]. Advances have also made it possible
for their use in genetic [2] and epigenetic analyses [3].
As such, DBS analyses can provide useful information in
epidemiologic studies of perinatal exposures such as
dietary nutrients and infectious agents, or to validate re-
ported exposure information (e.g., maternal tobacco use)
and for understanding (epi-) genetic mechanisms [4–7].
Residual newborn screening specimens represent a
unique, unbiased collection of population based mater-
ial. Universal newborn screening began in 1963 in four
U.S. states in response to Dr. Robert Guthrie’s discovery
of the screening test for phenylketonuria, a rare
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metabolic disorder that if untreated early in life leads to
disability [8]. Subsequently, Ireland and New Zealand
implemented screening procedures and currently 67
countries across the globe now have similar screening
programs [8]. Technologic advances have expanded the
number of metabolic, endocrine and other conditions
screened for, but vary by number in each U.S. State and
across different countries [9, 10].
Despite having Newborn Screening programs in all 50
US states [8] and elsewhere across the globe, few epide-
miologic studies have partnered with these programs to
augment research initiatives. Controversy surrounding
the ethical use of DBS and the differing policies of each
state’s program may present barriers for their use in re-
search [11, 12]. Studies have predominantly used DBS
anonymously in methodological work despite some indi-
cation that parents would support their non-anonymous
use [4, 13], while others have found that parents wanted
to be consented every time their child’s sample was used
[14]. Most recently, the Newborn Screening Saves Lives
Reauthorization Act has mandated that all federally
funded research on newborn DBS will require informed
consent with no exception [15]. Hence, both the feasibil-
ity of eliciting parental support and the characteristics of
those who provide consent compared to those who do
not, is important information that could be helpful to
pediatric researchers in designing future studies. This
paper describes the experience of the Upstate KIDS
study in eliciting parental consent and in retrieving DBS
with three objectives in mind. First, we describe the
process and the resources to acquire DBS for a
population-based cohort to help inform future study de-
sign. Second, we sought to evaluate the sociodemo-
graphic and perinatal factors associated with parental
consent for use of these specimens to identify subgroups
that may be disproportionately represented. Third, we
aimed to determine whether sufficient availability of re-
sidual specimen differed by participant characteristics.
Methods
The Upstate New York Infant Development Screening
Program (Upstate KIDS) [16] recruited 5,034 households
to study children’s growth and development from birth
through 3 years of age by mode of conception, as studies
had suggested that children conceived by infertility treat-
ment have poorer birth outcomes. Upstate KIDS en-
rolled infants born in Upstate New York (57 counties
excluding the 5 boroughs of New York City) from 2008
to 2010 at approximately 4 months postpartum. This
population based birth cohort recruited based on infer-
tility treatment information from birth certificates [16].
All singleton mothers who conceived with infertility
treatment and those conceived without infertility treat-
ment frequency matched on region of birth (at 1:3 ratio)
were recruited. Mothers of multiple births were also in-
vited to participate irrespective of infertility treatment
status. We previously compared the characteristics of
non-participants (n = 13,490) against participants finding
that non-Hispanic white race and higher socioeconomic
status (i.e., education, private insurance) to be associated
with participation [16]. Questionnaires assessing infant’s
development were mailed at 4, 8, 12, 18, 24, 30 and
36 months. The New York State Department of Health
(NYSDOH) and the University at Albany (State Univer-
sity of New York) Institutional Review Boards approved
the Study; and served as the Institutional Review Boards
designated by the National Institutes of Health for this
study under a reliance agreement. All parents provided
written informed consent at enrollment.
DBS consent process
We obtained additional parental consent when infants
were approximately 8 months of age for using residual
specimens from the Newborn Screening Program. Spe-
cifically, we asked permission to quantify immunologic
and environmental chemical biomarkers from remaining
DBS. We asked for permission to assess these bio-
markers of in utero infection or placental transfer of en-
vironmental chemicals for future work in assessing their
relation to adverse birth outcomes [17, 18] and early
childhood development [19–21]. Previous exploratory
research demonstrated the feasibility of measuring these
biomarkers irrespective of varying amounts of residual
blood extracted from DBSs [22–25]. More specifically,
DBS adipokines as measured by Upstate KIDS was asso-
ciated with birth size and gestational age in similar fash-
ion as results from cord blood measures by other studies
[26].
Informed consent documents were available in both
English and Spanish and were mailed to parents along
with the 8-month health assessment questionnaire. In-
formational brochures explaining the State’s Newborn
Screening Program were also included. To maximize re-
sponse, the consent explicitly stated that the measure-
ments were for cytokines and environmental chemicals,
but not medications or recreational drugs, and that no
genetic analyses will be performed. Voluntary participa-
tion was emphasized and made clear that the DBS
consent was not a required component of study partici-
pation. The consent included telephone numbers for the
site’s principal investigator and project coordinator, who
were available to answer questions.
Retrieval process
Up to 5 blood spots could be collected from each new-
born after birth by hospital staff [27]. New York State
(excluding the 5 boroughs of New York City) tested for
46 disorders at the time of our sampling. Among the
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consented infants participating in the Upstate KIDS
Study, identifying information was used to link their
birth certificates to the NYS Newborn Screening Pro-
gram to locate their DBS cards. Each filter paper card,
containing residual blood after newborn screening, was
pulled from cold storage (4 °C) by laboratory staff at the
Wadsworth Center, NYSDOH.24 For biomarker analyses,
including immunoglobulins and cytokines, five to six
3.2 mm punches were taken and assayed by the Immun-
ology Laboratory of the Wadsworth Center. Chemical
measurements required more blood volume or approxi-
mately 1–2 whole circles (~16 mm in diameter), and
were retrieved by the Environmental Laboratory staff of
the Wadsworth Center. By Newborn Screening policy,
one whole circle had to be preserved for future medical
indication. As such, specimens were only obtained if a
whole circle remained. When feasible, each lab punched
their samples from circles that had not been used by
Newborn Screening assuming sufficient remaining
sample for extended storages. Retrieval spanned from
2010 to 2013. Pulling and re-archiving the sample cards
alone took almost 800 h to complete at the rate of 10
cards per hour, or the equivalent of one full time em-
ployee for six months. A few unanticipated technical is-
sues arose, including static electricity affecting the
handling of blood spots, and the time-intensive nature
of extraction along with the availability of sufficient
space for obtaining the punches. On average, approxi-
mately 40 cards could be punched hourly. Photos of the
cards were taken before and after punching to document
their location in order to assess sampling variability in
future analyses (Fig. 1). We punched areas of the DBS
that had no obvious signs of double spotting in that
DBSs were reasonably symmetrical and the blood spot
area saturated the spot based on the redness of the op-
posite side of the Guthrie card. Harvested DBSs had no
Fig. 1 Example of before (a) and after (b) punching a DBS card. Five to six 3.2 mm punches were made by the Immunology Laboratory and 1–2
whole 16 mm punches were made by the Environmental Laboratory. One whole spot kept reserved for the Newborn Screening Program
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obvious signs of smearing or a plasma ring. Each DBS
circle was equivalent to approximately 50 ul of newborn
blood. The 3.2 mm punches for biomarker analyses were
equivalent to approximately 3.275 μl with 30 μl buffer
per punch. The amount of eluted sample remaining was
usually minimal to none for most analytes.
Covariate information
Baseline characteristics were obtained either from birth
certificates (i.e., maternal age, paternal age, region, plur-
ality, parity, insurance status, and infant birth outcomes)
or the mother’s baseline enrollment questionnaire ob-
tained at 4 months postpartum (e.g., marital/partnership
status). When information on a characteristic was avail-
able from both sources (i.e., maternal pre-pregnancy
weight, height, race, education, infertility treatment,
pregnancy smoking and alcohol use), maternal report
was used as the primary source of information and birth
certificates were used only if maternal report was un-
available (~2 %).
Statistical analysis
We first focused our analyses on factors associated
with household consent to use DBS. We implemented
univariate t-test and chi-square tests, as appropriate,
to identify factors associated with household consent.
Factors evaluated for possible impact on consent were
divided into two main areas: 1) household characteris-
tics such as maternal/paternal age, socioeconomics,
lifestyle and 2) infant factors such as birth outcomes
and failure of the first developmental screen. Factors
were selected based on issues that impact research
consent in general (e.g., race, socioeconomic status,
education), and issues that impact opting to partici-
pate in pediatric research (e.g., birth outcomes). Ana-
lyses were restricted to families who returned 8-
month survey materials (n = 3696, 73 %) as they
expressed continued response to the overall study and
differences in factors by consent status identified in
this group would not be a function of factors related
to overall response rates. Analyses of infant factors
were stratified by plurality as multiples are known to
have higher risk of adverse birth outcomes than sin-
gletons. Multiples included 771 twin and 35 triplet
sets. Infant factors were analyzed at the household
level as there were very few parents of multiples who
provided permission for one infant and not others.
To do so, households with multiples were regarded as
having an adverse event (e.g., NICU stay) if one (and
not necessarily all infants) experienced the event, with
the rationale that parents may be motivated to con-
sent all multiples even if just one experienced an ad-
verse event. As most multiples are preterm
(<37 weeks), we additionally investigated early
preterm birth defined as less than 32 weeks based on
the American College of Obstetricians and Gynecolo-
gists definition. All caesarean deliveries were as re-
ported on birth certificates regardless of indication
including non-emergency or scheduled. To quantify
the adjusted associations between factors and consent,
multivariate logistic regression was used to estimate
the odds ratio (OR) and 95 % confidence intervals
(CI) for consent.
Next, we assessed parental characteristics by successful
retrieval of DBS among those with consent. The units of
analysis were infants and adverse birth outcomes exam-
ined including NICU stay, Apgar below 7 at 5 min, Cae-
sarean delivery, ventilator use, preterm birth (<37 weeks)
and low birth weight (<2500 g). Generalized estimating
equations (GEE) were used to account for the correl-
ation between multiples. A parsimonious model includ-
ing factors that were statistically significant (p < 0.05)
from the univariate analyses was built to identify factors
associated with retrieval of a whole DBS for environ-
mental chemical analysis. As missing covariate data was
minimal (<5 %), imputation was not conducted (Table 1
footnotes). Statistical analyses were performed using
SAS 9.4 (SAS Institute, Cary, NC).
Results
Sixty-two percent (n = 3,125) of all enrolled households
(n = 5,034) consented to DBS use (Fig. 2). This propor-
tion did not differ by plurality with 60.9 % households of
multiples (n = 687 of 1129) providing consent. Parents of
multiples predominantly provided consent for all or
none of their infants with few discordant (i.e., 17 twins
and 3 triplets had discordant consent status from their
siblings). All but 16 infants whose parents consented
were successfully linked to the Newborn Screening Pro-
gram database. The inability to link was due primarily to
difficulties in distinguishing multiple birth sibships in a
set from one another (i.e., 15 of 16 were twins/triplets).
DBS were collected at a median of 2 days postpartum
(inter quartile range of 2–3 days). Of infants who linked,
99 and 84 % had sufficient remaining specimen for the
study by the Immunology and Environmental laborator-
ies, respectively; that is, 99 % had at least 3 mm diameter
of space to punch and 84 % had a full circle available.
Of the 3125 households with a returned consent,
3107 (99.4 %) returned other 8-month materials. As
this high proportion indicated that consent is condi-
tional on continuing response to the overall study,
Tables 1 and 2 show the differences in characteristics
by consent status restricted to those who returned
their infant 8-month questionnaire. Among those who
provided questionnaire responses, 84 % agreed to
DBS analyses. Few household/maternal characteristics
were identified as being associated with consent after
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mutual adjustment for other covariates (Table 1).
Women who were nulliparous or Hispanic were less
likely to consent whereas those who consumed any
alcohol in pregnancy or were obese were more likely
to significantly consent compared to their counter-
parts. Despite the significant odds ratios for these
characteristics, absolute differences ranged from 4 to
8 %, suggesting that the two groups remained
comparable.
As for infant outcomes, analyses stratified by plurality
showed that a greater percentage of consents were re-
ceived from households of multiples having adverse birth
outcomes (i.e., ventilator use, NICU stay, early preterm
birth) than homes of multiples without adverse outcomes.
Table 1 Baseline characteristics by Newborn Dried Blood Spot Consent Status for Upstate KIDS, New York (2008–2010)
Among those returning infant 8-month materials (n = 3696)
No Consent (n = 589) Consenta (n = 3107)
N (column %) No. % No. % OR (95 % CI) aOR (95 % CI)
Maternal age
<25 years 83 14 415 13 1.00 (reference) 1.00 (reference)
25 - < 30 years 170 29 779 25 0.92 (0.69–1.22) 0.78 (0.56–1.11)
30 - < 35 years 179 30 1031 33 1.15 (0.87–1.53) 0.91 (0.63–1.30)
35 years or older 157 27 882 28 1.12 (0.84–1.50) 0.88 (0.60–1.31)
Singleton pregnancy 469 80 2420 78 0.90 (0.73–1.12) 0.90 (0.71–1.13)
Maternal race/ethnicity
Non-hispanic White 460 78 2602 84 1.00 (reference) 1.00 (reference)
Non-hispanic Black 23 4 101 3 0.78 (0.49–1.23) 0.68 (0.41–1.14)
Non-hispanic Asian 11 2 91 3 1.46 (0.78–2.76) 1.64 (0.86–3.13)
Hispanic 61 10 134 4 0.39 (0.28–0.53) 0.40 (0.28–0.58)
Mixed / Other 34 6 179 6 0.93 (0.64–1.36) 0.94 (0.63–1.40)
Maternal education
Less than high school 33 6 129 4 0.78 (0.52–1.18) 1.04 (0.61–1.78)
HS or GED equivalent 59 10 330 11 1.12 (0.82–1.54) 1.21 (0.82–1.78)
Some college 165 28 888 29 1.08 (0.86–1.35) 1.08 (0.84–1.41)
College 132 22 763 25 1.16 (0.91–1.47) 1.19 (0.92–1.52)
Advanced degree 200 34 997 32 1.00 (reference) 1.00 (reference)
Private Insurance 463 79 2476 80 1.07 (0.86–1.33) 1.07 (0.81–1.42)
Married/Living as married 512 92 2736 91 0.89 (0.64–1.23) 0.81 (0.56–1.16)
Nulliparous 314 54 1420 46 0.73 (0.61–0.87) 0.71 (0.58–0.87)
Any alcohol during pregnancy 55 9 422 14 1.52 (1.13–2.05) 1.53 (1.13–2.08)
Smoked during pregnancy 51 9 345 11 1.32 (0.97–1.79) 1.15 (0.82–1.62)
Infertility treatment
None 396 67 2096 67 1.00 (reference) 1.00 (reference)
Drugs only 106 18 517 17 0.92 (0.73–1.17) 0.95 (0.73–1.23)
ART 87 15 493 16 1.07 (0.83–1.38) 1.15 (0.86–1.55)
Prepregnancy BMI categories
Normal weight (BMI <25) 341 55 1598 49 1.00 (reference) 1.00 (reference)
Overweight (BMI 25–30) 132 24 757 26 1.22 (0.98–1.52) 1.25 (0.99–1.57)
Obese (BMI ≥30) 114 21 745 25 1.39 (1.11–1.75) 1.43 (1.12–1.83)
aIncludes: 16 who could not link to newborn screening: 1 singleton, 11 twins, 4 triplets (due to unclear which child of the set); Excludes 18 who had only provided
blood spot consent
Bolded for significance (p < 0.05)
aORs adjusted for all other household/maternal factors in the Table
Total N for the models were reduced due to missing information: 1 for specific type of infertility treatment, 2 for insurance status, 126 for marital status, 28 for
parity, 2 for alcohol, 2 for smoking, and 9 for BMI
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These associations were not evident among households
with singleton births. After adjustment for significant par-
ental characteristics from Table 1 (i.e., race, alcohol use,
parity, BMI), only ventilator use (OR 1.95, 95 % CI: 1.13–
3.36) remained a significant factor for consent among
multiples whereas NICU stay (OR 1.12; 0.81–1.56) and
early preterm birth (OR 1.51; 0.82–2.78) did not remain
significant. There were no significant associations for sin-
gletons in adjusted models (p > 0.10) (data not shown).
Among infants with consent received for DBS ana-
lysis (n = 3782), very few factors were significantly
associated with their spots not being retrieved (n =
609) by the Environmental Lab which required at
least one whole DBS circle (Table 3). In multivariate
analysis, having an infant who required a NICU stay
compared to not and less than high school education
compared with advanced degree remained significant
factors for inability to retrieve a whole circle.
Discussion
Our experience in New York State (excluding New York
City) demonstrates that residual DBS are a feasible way
n=5,034 households 
(6,171 children)
3,125 (62%) parents 
consented for their 3,818 
children
Collected six 3mm punches for 
biomarker analyses: 3730 (98.6%)
- 18 blood spot consent only 
- 16 did not link to NBS
3,784 infants linked to Newborn Screening
Collected 1-2 full spots for chemical 
analyses: 3175 (83.9%)
54 unavailable - 564 not collected 
- 45 unavailable 
Fig. 2 Flowchart outlining newborn dried blood spot retrieval of punches for Upstate KIDS
Table 2 Birth outcomes of consented participants for Newborn Dried Blood Spot analyses stratified by plurality among households
returning the 8-month packets for Upstate KIDS, New York (2008–2010)
Singletons (2889 households) Multiples (807 households)
Non-consent Consent p-value Non-consent Any Consent p-value
N (row %) 469 (16) 2420 (84) n/a 120 (15) 687 (85)
Ventilator 9 (2) 84 (3) 0.08 8 (7) 124 (16) 0.002
NICU 29 (6) 174 (7) 0.43 40 (33) 300 (44) 0.03
Cesarean section (any) 187 (40) 931 (38) 0.57 103 (86) 536 (78) 0.05
Preterm (<37 weeks) 31 (7) 185 (8) 0.44 57 (48) 374 (55) 0.22
Early preterm (<32 weeks) 6 (1) 43 (2) 0.45 10 (4) 129 (11) 0.006
Low birth weight (<2500 g) 21 (4) 124 (5) 0.56 74 (62) 423 (62) 0.93
Deaths n/a n/a 1 (1) 31 (4) 0.07
N (column %) unless indicated. N = number of households/mothers with conditions specified as “any” or “all” multiples as there were few discordant between
twins in consent (i.e., 17 twins had discordant consent status with their co-twin). There were few triplets (33 sets consented, 2 not) and quadruplets (none
consented, 1 set consented) so data not shown
p-value by chi-square or Fisher’s exact test (for n < 5)
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to obtain biological samples to augment a population
based cohort study. Over 60 % of the cohort con-
sented to DBS use with the proportion increasing to
84 % among those who indicated continued partici-
pation in the study through return of other 8-month
materials. With the Newborn Screening Saves Lives
Reauthorization Act of 2014 requiring consent for
use of residual DBS, our results are reassuring that
the majority of parents would be supportive of such
research efforts and that obtaining consent should
not be a deterrent for leveraging this valuable
resource. We also demonstrated highly successful
retrieval with success for 99 % of consented infants
when only 3 mm punches are needed and 84 % even
when a whole blood spot circle is required for
analyses.
Policies on using DBS vary widely and multiple inter-
national organizations wrestle with their ethical use [11,
28–31]. Debate continues whether all uses (even when
de-identified) should require parental consent [31]. A
study using focus groups of expectant parents identified
typical concerns with using residual DBS in research, in-
cluding understanding the use of the DBS and the
methods for safeguarding the information, especially in
cases where it may cause potential discrimination for
their children [13]. On the other hand, parents from the
focus group wanted to know the results and viewed an-
onymous research as actually less beneficial [13]. How-
ever, the acceptability of anonymous research remains
high. A new consent protocol was introduced in
Victoria, Australia which asked parents’ permission to
use remaining newborn screening samples in de-
identified health research [32]. For over 77,000 new-
borns, only 6.5 % of parents declined the use of their
child’s residual DBS in secondary research and another
1.4 % did not respond [32]. Our finding that the majority
of parents are willing to provide consent concurs with
their study. However, one weakness of our study was
that we did not actively reach out to parents with miss-
ing DBS consents to confirm their opinions of DBS use.
Face-to-face contact may have also increased our
response as other studies have found with respect to re-
cruitment [33].
Our success was due to crucial partnerships with
the New York State Department of Health including
Newborn Screening and the other laboratories of the
Wadsworth Center; our experience may not be
generalizable to all states as state policies on their
use vary widely. Given the importance of involving
stakeholders in research, as exemplified by the estab-
lishment of the Patient-Centered Outcomes Research
Institute (PCORI) [34], such collaborations will likely
increase in the future. Bringing together parents, de-
partments of health and research institutions could
assist with establishing neonatal research priorities. A
national feasibility study attempting to retrieve DBS
from across the US found significant geographic vari-
ability in DBS retrieval rates [35]. Of note, New York
was one of the states where investigators had success
in retrieving DBS samples [35]. The study found a
similar consent rate (58 %) as ours (62 %) when re-
stricted to families that were reached. These consent
rates support findings from another survey [36] and
indicate that the majority of the population condones
the use of residual DBS for research purposes regard-
less of whether the family had a sick child (e.g.,
pediatric cancer [35]) or a more general population
(e.g., Upstate KIDS). Other states may not release
DBS for research use and some states do not retain
specimens for more than a year [28]. In such states,
research using residual DBS would have to seek con-
sent prior to or just after birth to ensure prolonged
storage, allowing for later retrieval. In our study, re-
trieval occurred 1–5 years after birth. Recent recom-
mendations to include DBS card serial numbers on
birth certificates [37] may make retrieval for studies
easier.
We acknowledge that many European cohort stud-
ies have successfully collected cord blood samples for
Table 3 Odds ratios (95 % CI) to identify factors for newborn
dried blood spots not being collected among infants with
parental consent in Upstate KIDS, New York (2008–2010)
N (collected/not collected) 3782 (3173/609)a
Crude OR
for not collected
aOR (95 % CI)
Multiple birth 1.21 (1.01, 1.44) 1.05 (0.85, 1.31)
Private insurance 0.82 (0.68, 0.98) 0.97 (0.78, 1.20)
Maternal race/ethnicity
Non-hispanic white 1.00 (reference) 1.00 (reference)
Non-hispanic Black 0.68 (0.39, 1.20) 0.61 (0.35, 1.06)
Non-hispanic Asian 0.99 (0.61, 1.60) 1.03 (0.64, 1.67)
Hispanic 1.39 (1.00, 1.93) 1.20 (0.86, 1.67)
Mixed race or ethnicity / Other 0.95 (0.66, 1.36) 0.92 (0.65, 1.31)
Maternal education
Less than high school 1.78 (1.31, 2.42) 1.68 (1.19, 2.37)
HS or GED equivalent 1.20 (0.92, 1.57) 1.19 (0.90, 1.59)
Some college 1.03 (0.84, 1.27) 1.03 (0.83, 1.27)
College 0.78 (0.62, 0.99) 0.77 (0.61, 0.98)
Advanced degree 1.00 (reference) 1.00 (reference)
NICU 1.44 (1.21, 1.71) 1.33 (1.05, 1.67)
Ventilator (any) 1.28 (1.03, 1.60) 1.18 (0.93, 1.50)
Preterm (<37 weeks) 1.27 (1.05, 1.53) 0.93 (0.70, 1.23)
Low birth weight (<2500 g) 1.27 (1.08, 1.49) 1.14 (0.92, 1.42)
a 2 missing insurance status
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their birth cohorts and may not have to rely on
stored blood spots [38]. However, for areas of the
world where the cost or the logistics of collecting
specimens are prohibitive (e.g., for home births), we
demonstrate that DBS is an alternative acceptable to
most parents. Many international research studies
have also turned to DBS due to its minimal invasive-
ness and feasibility without relying on trained phle-
botomists [39]. Moreover, the infrastructure for the
collection is already established, making it a great re-
source for population based studies. The Wadsworth
Center also has established methods to measure im-
munological [22] and environmental chemical markers
[23–25] and successfully completed the analysis in the
samples collected for the Upstate KIDS study, demon-
strating feasibility. Of note, cord blood collected at
delivery may be different from that obtained on blood
spots that are typically collected 2–3 days postpartum.
However, cohort studies are also moving towards
collecting blood spots longitudinally throughout
childhood due to their greater acceptability over
venipuncture among healthy children as well as less
logistical burden than serum/plasma collection requir-
ing centrifugation [40].
Over 80 % of parents who returned the 8-month
study questionnaires consented to the use of DBS.
Consent may differ if we had not explicitly excluded
genetic or pharmacologic tests on the consent forms,
described pilot tests for detecting new disorders as
part of newborn screening, or if parents were not
part of an ongoing cohort study. As participants had
self-selected into the parent study, they may have had
a more positive view of health research or might have
also wanted additional contact with the medical sys-
tem which could bias them towards consenting. We
identified very few factors significantly associated with
consent, including Hispanic race, parity, alcohol use,
and maternal obesity. We had a predominantly white
(80 %) cohort, and our ethnic difference in consent,
based on <200 Hispanic households, may not be
generalizable to all studies. However, among our par-
ticipants, factors that are typically regarded as barriers
to participation and possible reasons for ethnic
disparities [41], such as access to research, language,
or time were eliminated by availability of Spanish
language materials and return of materials by mail ra-
ther than clinic visit. Our findings may not be
broadly generalizable to all population based studies
due to low initial response rate for participating in
the study (22 %) [16] and the attrition (27 %) experi-
enced at the time of DBS consent. One recent meta-
analysis has contradicted the perception of minority
mistrust, finding that minorities are as willing, or
even more willing to participate in research studies
than non-Hispanic whites, although considerable het-
erogeneity between studies was acknowledged [41].
Greater understanding of the rationale for not con-
senting may be helpful for future studies especially
among minorities.
Conclusion
Researchers should consider residual DBS as a source of
biological specimens from newborns for population-
based cohort studies. We presented the technical efforts
used for such an undertaking so that future researchers
can plan for the necessary resources required. Newborn
blood spot registries offer novel opportunities for re-
search aimed at understanding children’s health, particu-
larly in relation to in utero exposures that can be
quantified using banked specimens. Undoubtedly safe-
guards of this resource need continual evaluation, given
concerns previously raised for their ethical use [11].
Nevertheless in our study, the majority of parents agreed
with this practice. We demonstrate in New York State
(excluding New York City) that retrieval of one whole
circle from filter paper card was successful for over 80 %
of infants whose parents consented to the study, and al-
most all (99 %) had a sufficient number of 3.2 mm
punches available.
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